MedTrace Logo

Clinical Evaluation for Sarcoma Originated From Bone

NCT03358992 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 300

Last updated 2018-11-14

No results posted yet for this study

Summary

Response Evaluation Criteria in Solid Tumors (RECIST) are insensitive in evaluating primary sarcoma originated from bone treated with chemotherapy or targeted therapy, which did not have the definition of measurement methods either. This study evaluates whether clinical imaging findings of sarcoma after preoperative chemotherapy correlate with tumor responses by pathological evaluation by Huvos classifications and develops reliable, quantitative, clinical response criteria.

Conditions

  • Sensitivity
  • Specificity
  • Histological Response
  • Survival

Sponsors & Collaborators

  • Xijing Hospital

    collaborator OTHER

  • Second Affiliated Hospital, School of Medicine, Zhejiang University

    collaborator OTHER

  • Peking University People's Hospital

    lead OTHER

Principal Investigators

  • Wei Guo · Musculoskeletal Tumor Center of Peking University People's Hospital

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-01-01
Primary Completion
2018-12-30
Completion
2019-03-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03358992 on ClinicalTrials.gov